|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Egan A, Dong Y, Zhang H, Qi Y, Balk SP and
Sartor O: Castration-resistant prostate cancer: Adaptive responses
in the androgen axis. Cancer Treat Rev. 40:426–433. 2014.
View Article : Google Scholar
|
|
4
|
van Soest RJ, Nieuweboer AJ, de Morrée ES,
Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de
Wit R, et al: Dutch Uro-Oncology Studygroup (DUOS): The influence
of prior novel androgen receptor targeted therapy on the efficacy
of cabazitaxel in men with metastatic castration- resistant
prostate cancer. Eur J Cancer. 51:2562–2569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al Nakouzi N, Le Moulec S, Albigès L, Wang
C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A,
Gajda D, Massard C, et al: Cabazitaxel remains active in patients
progressing after docetaxel followed by novel androgen receptor
pathway targeted therapies. Eur Urol. 68:228–235. 2015. View Article : Google Scholar
|
|
6
|
Mezynski J, Pezaro C, Bianchini D, Zivi A,
Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A,
et al: Antitumour activity of docetaxel following treatment with
the CYP17A1 inhibitor abiraterone: Clinical evidence for
cross-resistance? Ann Oncol. 23:2943–2947. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Soest RJ, van Royen ME, de Morrée ES,
Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R and van
Weerden WM: Cross-resistance between taxanes and new hormonal
agents abiraterone and enzalutamide may affect drug sequence
choices in metastatic castration-resistant prostate cancer. Eur J
Cancer. 49:3821–3830. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chung Moh M, Hoon Lee L and Shen S:
Cloning and characterization of hepaCAM, a novel Ig-like cell
adhesion molecule suppressed in human hepatocellular carcinoma. J
Hepatol. 42:833–841. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu B, He Y, Wu X, Luo C, Liu A and Zhang
J: Exploration of the correlations between interferon-γ in patient
serum and HEPACAM in bladder transitional cell carcinoma, and the
interferon-γ mechanism inhibiting BIU-87 proliferation. J Urol.
188:1346–1353. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xun C, Luo C, Wu X, Zhang Q, Yan L and
Shen S: Expression of hepaCAM and its effect on proliferation of
tumor cells in renal cell carcinoma. Urology. 75:828–834. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang XL, Zhang Y, Tan B, Luo CL and Wu
XH: Renal tumor-derived exosomes inhibit hepaCAM expression of
renal carcinoma cells in a p-AKT-dependent manner. Neoplasma.
61:416–423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tao J, Liu Q, Wu X, Xu X, Zhang Y, Wang Q
and Luo C: Identification of hypermethylation in hepatocyte cell
adhesion molecule gene promoter region in bladder carcinoma. Int J
Med Sci. 10:1860–1867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Du HF, Ou LP, Lv CK, Yang X, Song XD, Fan
YR, Wu XH and Luo CL: Expression of hepaCAM inhibits bladder cancer
cell proliferation via a Wnt/β-catenin-dependent pathway in vitro
and in vivo. Cancer Biol Ther. 16:1502–1513. 2015. View Article : Google Scholar
|
|
14
|
Wang Q, Luo C, Wu X, Du H, Song X and Fan
Y: hepaCAM and p-mTOR closely correlate in bladder transitional
cell carcinoma and hepaCAM expression inhibits proliferation via an
AMPK/mTOR dependent pathway in human bladder cancer cells. J Urol.
190:1912–1918. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Quan Z, He Y, Luo C, Xia Y, Zhao Y, Liu N
and Wu X: Interleukin 6 induces cell proliferation of clear cell
renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent
up-regulation of DNMT1 or DNMT3b. Cell Signal. 32:48–58. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang T, Moh MC, Lee LH and Shen S: The
immunoglobulin-like cell adhesion molecule hepaCAM is cleaved in
the human breast carcinoma MCF7 cells. Int J Oncol. 37:155–165.
2010.PubMed/NCBI
|
|
17
|
Song X, Wang Y, Du H, Fan Y, Yang X, Wang
X, Wu X and Luo C: Overexpression of HepaCAM inhibits cell
viability and motility through suppressing nucleus translocation of
androgen receptor and ERK signaling in prostate cancer. Prostate.
74:1023–1033. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guruharsha KG, Kankel MW and
Artavanis-Tsakonas S: The Notch signalling system: Recent insights
into the complexity of a conserved pathway. Nat Rev Genet.
13:654–666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kwon OJ, Valdez JM, Zhang L, Zhang B, Wei
X, Su Q, Ittmann MM, Creighton CJ and Xin L: Increased Notch
signalling inhibits anoikis and stimulates proliferation of
prostate luminal epithelial cells. Nat Commun. 5:44162014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bin Hafeez B, Adhami VM, Asim M, Siddiqui
IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V and Mukhtar H:
Targeted knockdown of Notch1 inhibits invasion of human prostate
cancer cells concomitant with inhibition of matrix
metalloproteinase-9 and urokinase plasminogen activator. Clin
Cancer Res. 15:452–459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Santagata S, Demichelis F, Riva A,
Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE,
Chinnaiyan AM, et al: JAGGED1 expression is associated with
prostate cancer metastasis and recurrence. Cancer Res.
64:6854–6857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cui D, Dai J, Keller JM, Mizokami A, Xia S
and Keller ET: Notch pathway inhibition using PF-03084014, a
γ-secretase inhibitor (GSI), enhances the antitumor effect of
docetaxel in prostate cancer. Clin Cancer Res. 21:4619–4629. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo Y, Zhang K, Cheng C, Ji Z, Wang X,
Wang M, Chu M, Tang DG, Zhu HH and Gao WQ: Numb−/low
enriches a castration-resistant prostate cancer cell subpopulation
associated with enhanced notch and hedgehog signaling. Clin Cancer
Res. 23:6744–6756. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stoyanova T, Riedinger M, Lin S,
Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK,
Drake JM, et al: Activation of Notch1 synergizes with multiple
pathways in promoting castration-resistant prostate cancer. Proc
Natl Acad Sci USA. 113:E6457–E6466. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Wu X, Ou L, Yang X, Wang X, Tang
M, Chen E and Luo C: PLCε knockdown inhibits prostate cancer cell
proliferation via suppression of Notch signalling and nuclear
translocation of the androgen receptor. Cancer Lett. 362:61–69.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wei P, Walls M, Qiu M, Ding R, Denlinger
RH, Wong A, Tsaparikos K, Jani JP, Hosea N, Sands M, et al:
Evaluation of selective gamma-secretase inhibitor PF-03084014 for
its antitumor efficacy and gastrointestinal safety to guide optimal
clinical trial design. Mol Cancer Ther. 9:1618–1628. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yabuuchi S, Pai SG, Campbell NR, de Wilde
RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M,
Maitra A, et al: Notch signaling pathway targeted therapy
suppresses tumor progression and metastatic spread in pancreatic
cancer. Cancer Lett. 335:41–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arcaroli JJ, Quackenbush KS, Purkey A,
Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song
EK, et al: Tumours with elevated levels of the Notch and Wnt
pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor,
in a preclinical colorectal explant model. Br J Cancer.
109:667–675. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: European Association of Urology: EAU guidelines
on prostate cancer. Part II: Treatment of advanced, relapsing, and
castration-resistant prostate cancer. Eur Urol. 65:467–479. 2014.
View Article : Google Scholar
|
|
30
|
Matei DV, Renne G, Pimentel M, Sandri MT,
Zorzino L, Botteri E, De Cicco C, Musi G, Brescia A, Mazzoleni F,
et al: Neuroendocrine differentiation in castration-resistant
prostate cancer: A systematic diagnostic attempt. Clin Genitourin
Cancer. 10:164–173. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
32
|
Kuruma H, Matsumoto H, Shiota M, Bishop J,
Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, et al:
A novel antiandrogen, compound 30, suppresses castration-resistant
and MDV3100-resistant prostate cancer growth in vitro and in vivo.
Mol Cancer Ther. 12:567–576. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kawata H, Ishikura N, Watanabe M,
Nishimoto A, Tsunenari T and Aoki Y: Prolonged treatment with
bicalutamide induces androgen receptor overexpression and androgen
hypersensitivity. Prostate. 70:745–754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kawabata R, Oie S, Oka T, Takahashi M,
Kanayama H and Itoh K: Hydroxyflutamide enhances cellular
sensitivity to 5-fluorouracil by suppressing thymidylate synthase
expression in bicalutamide-resistant human prostate cancer cells.
Int J Oncol. 38:665–676. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Takeda M, Mizokami A, Mamiya K, Li YQ,
Zhang J, Keller ET and Namiki M: The establishment of two
paclitaxel-resistant prostate cancer cell lines and the mechanisms
of paclitaxel resistance with two cell lines. Prostate. 67:955–967.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Govindan SV, Cardillo TM, Moon SJ, Hansen
HJ and Goldenberg DM: CEACAM5-targeted therapy of human colonic and
pancreatic cancer xenografts with potent labetuzumab-SN-38
immunoconjugates. Clin Cancer Res. 15:6052–6061. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Han SU, Kwak TH, Her KH, Cho YH, Choi C,
Lee HJ, Hong S, Park YS, Kim YS, Kim TA, et al: CEACAM5 and CEACAM6
are major target genes for Smad3-mediated TGF-beta signaling.
Oncogene. 27:675–683. 2008. View Article : Google Scholar
|
|
38
|
Kirshner J, Chen CJ, Liu P, Huang J and
Shively JE: CEACAM1-4S, a cell-cell adhesion molecule, mediates
apoptosis and reverts mammary carcinoma cells to a normal
morphogenic phenotype in a 3D culture. Proc Natl Acad Sci USA.
100:521–526. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Weigelt B, Ghajar CM and Bissell MJ: The
need for complex 3D culture models to unravel novel pathways and
identify accurate biomarkers in breast cancer. Adv Drug Deliv Rev.
69–70:42–51. 2014. View Article : Google Scholar
|
|
40
|
Stubblefield K, Chean J, Nguyen T, Chen CJ
and Shively JE: The adaptor SASH1 acts through NOTCH1 and its
inhibitor DLK1 in a 3D model of lumenogenesis involving CEACAM1.
Exp Cell Res. 359:384–393. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Danza G, Di Serio C, Ambrosio MR, Sturli
N, Lonetto G, Rosati F, Rocca BJ, Ventimiglia G, del Vecchio MT,
Prudovsky I, et al: Notch3 is activated by chronic hypoxia and
contributes to the progression of human prostate cancer. Int J
Cancer. 133:2577–2586. 2013.PubMed/NCBI
|
|
42
|
Zhu H, Zhou X, Redfield S, Lewin J and
Miele L: Elevated Jagged-1 and Notch-1 expression in high grade and
metastatic prostate cancers. Am J Transl Res. 5:368–378.
2013.PubMed/NCBI
|
|
43
|
Domingo-Domenech J, Vidal SJ,
Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco
R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J,
et al: Suppression of acquired docetaxel resistance in prostate
cancer through depletion of notch- and hedgehog-dependent
tumor-initiating cells. Cancer Cell. 22:373–388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang QL, Luo CL, Wu XH, Wang CY, Xu X,
Zhang YY, Liu Q and Shen SL: HepaCAM induces G1 phase arrest and
promotes c-Myc degradation in human renal cell carcinoma. J Cell
Biochem. 112:2910–2919. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tang M, Zhao Y, Liu N, Chen E, Quan Z, Wu
X and Luo C: Overexpression of HepaCAM inhibits bladder cancer cell
proliferation and viability through the AKT/FoxO pathway. J Cancer
Res Clin Oncol. 143:793–805. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu M, Moh MC and Schwarz H: HepaCAM
associates with connexin 43 and enhances its localization in
cellular junctions. Sci Rep. 6:362182016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yap TA, Smith AD, Ferraldeschi R,
Al-Lazikani B, Workman P and de Bono JS: Drug discovery in advanced
prostate cancer: Translating biology into therapy. Nat Rev Drug
Discov. 15:699–718. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sharp A, Welti J, Blagg J and de Bono JS:
Targeting androgen receptor aberrations in castration-resistant
prostate cancer. Clin Cancer Res. 22:4280–4282. 2016. View Article : Google Scholar
|
|
49
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: TAX 327 Investigators: Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang CC, Pavlicek A, Zhang Q, Lira ME,
Painter CL, Yan Z, Zheng X, Lee NV, Ozeck M, Qiu M, et al:
Biomarker and pharmacologic evaluation of the γ-secretase inhibitor
PF-03084014 in breast cancer models. Clin Cancer Res. 18:5008–5019.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Papayannidis C, DeAngelo DJ, Stock W,
Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA,
Ozeck M, et al: A Phase 1 study of the novel gamma-secretase
inhibitor PF-03084014 in patients with T-cell acute lymphoblastic
leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J.
5:e3502015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Carol H, Maris JM, Kang MH, Reynolds CP,
Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, et
al: Initial testing (stage 1) of the notch inhibitor PF-03084014,
by the pediatric preclinical testing program. Pediatr Blood Cancer.
61:1493–1496. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kummar S, O'Sullivan Coyne G, Do KT,
Turkbey B, Meltzer PS, Polley E, Choyke PL, Meehan R, Vilimas R,
Horneffer Y, et al: Clinical activity of the γ-secretase inhibitor
PF-03084014 in adults with desmoid tumors (aggressive
fibromatosis). J Clin Oncol. 35:1561–1569. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lombardo Y, Faronato M, Filipovic A,
Vircillo V, Magnani L and Coombes RC: Nicastrin and Notch4 drive
endocrine therapy resistance and epithelial to mesenchymal
transition in MCF7 breast cancer cells. Breast Cancer Res.
16:R622014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yun J, Pannuti A, Espinoza I, Zhu H, Hicks
C, Zhu X, Caskey M, Rizzo P, D'Souza G, Backus K, et al: Crosstalk
between PKCα and Notch-4 in endocrine-resistant breast cancer
cells. Oncogenesis. 2:e602013. View Article : Google Scholar
|
